Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DABRAFENIB vs OSIMERTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DABRAFENIB vs OSIMERTINIB: Safety Overview

Metric DABRAFENIB OSIMERTINIB
Total FAERS Reports 19,305 27,750
Deaths Reported 4,165 12,456
Death Rate 21.6% 44.9%
Hospitalizations 5,325 5,277
Average Patient Age 58.3 yrs 68.2 yrs
% Female Patients 48.0% 66.0%
FDA Approval Date Mar 16, 2023 Nov 13, 2015
Manufacturer Novartis Pharmaceuticals Corporation AstraZeneca Pharmaceuticals LP
Route ORAL ORAL
Marketing Status Prescription Prescription